In this study, YLZD treatment upregulates the expression of SIRT1, Nrf2 and improves the activities of anti-oxidative factors such as NQO-1, HO-1, SOD and GSH-Px in HFD-induced NAFLD rats. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatotic liver disease.